Rapid health technology assessment of serplulimab in the first-line treatment of small-cell lung cancer
- VernacularTitle:斯鲁利单抗一线治疗小细胞肺癌的快速卫生技术评估
- Author:
Yibing HOU
1
;
Shuo KANG
2
;
Yuan GONG
3
;
Xiaohui WANG
3
;
Ying NIE
3
;
Huanlong LIU
2
Author Information
1. Dept. of Pharmacy，the Second Hospital of Hebei Medical University，Shijiazhuang 050000，China
2. Medical Insurance Office，the Second Hospital of Hebei Medical University，Shijiazhuang 050000，China
3. School of Pharmacy，Hebei Medical University，Shijiazhuang 050017，China
- Publication Type:Journal Article
- Keywords:
serplulimab;
small-cell lung cancer;
effectiveness;
safety;
cost-effectiveness;
rapid health technology assessment
- From:
China Pharmacy
2025;36(11):1405-1410
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the efficacy， safety and cost-effectiveness of serplulimab as a first-line treatment of small- cell lung cancer （SCLC）， and provide an evidence-based basis for drug selection in hospitals. METHODS Rapid health technology assessment was adopted； PubMed， Cochrane Library， Embase， CNKI， Wanfang， VIP and official websites of domestic and international health technology assessment agencies were systematically searched from the inception to Oct. 2024. Two reviewers independently screened the literature， assessed the quality of included studies and carried out the qualitative analysis according to the inclusion and exclusion criteria. RESULTS A total of 13 systematic reviews/meta-analyses and 9 economic studies were included， and the literature quality was generally good. In terms of effectiveness， compared with chemotherapy alone， serplulimab combined with chemotherapy significantly improved progression-free survival， overall survival， and objective response rate in patients with SCLC. In terms of safety， serplulimab combined with chemotherapy showed no significant difference in the incidence of ≥3 grade adverse events compared with chemotherapy alone in the treatment of SCLC， indicating a good safety profile； compared with combination therapies involving other immunosuppressive agents， the incidence rate of adverse events was also lower. In terms of cost-effectiveness， compared with chemotherapy alone， serplulimab combined with chemotherapy is not cost- effective， which may be related to the high price of serplulimab. CONCLUSIONS Serplulimab is effective and safe in the treatment of SCLC， but has no obvious advantage in terms of cost-effectiveness.
